Mini-strokes don't cause permanent damage, however, it's a warning sign of a possible full-blown stroke ahead. When you first ...

Study findings suggest the therapeutic window for DAPT benefit may extend up to 42 hours, but risk increases after 72 hours.

A new predictive tool may help identify patients at risk for poststroke dementia, potentially accelerating research and ...

Bayer today presented the results from the global, pivotal Phase III OCEANIC-STROKE study evaluating the use of its ...

The rationale behind the treatment is that, because genetic FXI deficiency has been linked with reduced risk of ischemic ...

A 26% relative hazard reduction in recurrent ischemic stroke was observed (HR 0.74), with primary efficacy assessed as time to first ischemic stroke. OCEANIC-STROKE trial data show asundexian cuts ...

A new risk calculator accurately estimated the likelihood of adults developing dementia within ten years after a stroke, according to a preliminary study to be presented at the American Stroke ...

An investigational anti-clotting medication, asundexian, demonstrated a reduction in the risk of a second ischemic ...

For patients with noncardioembolic ischemic stroke or high-risk transient ischemic attack, asundexian, a factor XIa inhibitor ...

Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and ...

In a U.S. ED observation TIA cohort, transthoracic echocardiography identified high risk cardioembolic features in nearly 1 in 5, most often patent foramen ovale and reduced LVEF.